Comparative Pharmacology
Head-to-head clinical analysis: NORCET versus OPANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORCET versus OPANA.
NORCET vs OPANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination analgesic: hydrocodone acts as a μ-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates endocannabinoid system, exerting central analgesic and antipyretic effects.
Mu-opioid receptor agonist; produces analgesia by binding to opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception.
1-2 tablets (containing paracetamol 325 mg and tramadol 37.5 mg) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
5-20 mg orally every 4-6 hours as needed for pain; extended-release tablets: 5 mg orally every 12 hours, titrated up to 20 mg every 12 hours.
None Documented
None Documented
2-4 hours (terminal); prolonged in hepatic impairment (up to 8-10 hours) and elderly
Terminal elimination half-life is 11-16 hours (mean 14 hours) in adults; prolonged in hepatic impairment (up to 30 hours) and elderly.
Renal: ~60% unchanged; hepatic metabolism to inactive glucuronide conjugates; biliary/fecal: <5%
Primarily renal (approximately 90% as conjugated metabolites, 10% unchanged); biliary/fecal elimination accounts for <10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic